RCT – Page 22 – Communicable Diseases Research

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions

Open Letter

Published on 2021-09-212022-10-28
Journal: Wellcome Open Research [Category] COVID-19,

Melatonin as an Add-On Treatment of COVID-19 Infection: Current Status

Communication

Published on 2021-09-202022-11-01
Journal: Diseases [Category] COVID-19,

[키워드] acting addition antibody antioxidant cellular Complete conceive conducted contrary COVID-19 Critical CRP current Cytokines discharge Diseases distribution dysregulated Evidence gastrointestinal tract hospitalized COVID-19 patients Humoral immunity Immunity Infection low dose mechanism melatonin Mitochondria modulating Numerous Perspective proinflammatory cytokines radical scavenger randomized controlled study Randomized controlled trial RCT receptor repeated reported representing response Retina shown Side effects significantly status Support Symptom target the SARS-CoV-2 virus therapy for COVID-19 tissue tissues Trial
[DOI] 10.3390/diseases9030064 PMC 바로가기 [Article Type] Communication

Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review

Medicine

Published on 2021-09-202022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

ACTION-1: study protocol for a randomised controlled trial on ACT-guided heparinization during open abdominal aortic aneurysm repair

ACTION-1: 개방 복부 대동맥류 수리 중 ACT 유도 헤파린 처리에 대한 무작위 대조 시험 연구 프로토콜

Study Protocol

Published on 2021-09-192022-09-10
Journal: Trials [Category] SARS, 임상,

[키워드] 30-Day mortality A significant reduction Abdominal aortic aneurysm Activated clotting time Admission Aneurysm Aneurysmal anticoagulation aortic aneurysm applied benefit bleeding blind Blood blood loss caused Clotting time Complication complications contrary data set Date decrease development disease dose eligible Endpoint enrolment EudraCT Europe evaluate exclusion criteria expected Germany GRADE Grade 1 healthy healthy volunteers heparin Hospital stay in-hospital mortality incidence Inclusion increase International less major bleeding Mesenteric artery Mortality Netherland Netherlands open Open repair operation Patient patients phase primary efficacy endpoint protocol Public randomised randomised controlled trial Randomized RCT re-operation reached recruitment reduce Registration repair report research and development Sample size secondary secondary outcome Sponsor Standard Standard of care Study protocol superior mesenteric artery supplementary material Support target TEC the patient Treatment Trial Trial registration undergo Vascular surgery
[DOI] 10.1186/s13063-021-05552-7 PMC 바로가기 [Article Type] Study Protocol

Chinese herbal medicine (“3 medicines and 3 formulations”) for COVID ‐19: rapid systematic review and meta‐analysis

COVID -19의 중국 약초 (“3 개의 의약품 및 3 개의 제형”) : 빠른 체계적인 검토 및 메타 분석

Review

Published on 2021-09-162022-08-31
Journal: Journal of Evaluation in Clinical Practice [Category] COVID19(2023년), MERS, SARS, 임상, 치료제,

[키워드] alleviate Alter article Baidu Chest CT Chinese clinical trial registries clinical trial registry CNKI COVID COVID‐19 COVID‐19 demonstrated disease severity effective evaluate Evidence Final groups Herbal herbal medicine Impact inclusion criteria Laboratory Manifestations Medicine meta‐analysis methodological limitations outcome outcomes participant Primary outcome random effect randomized trial RCT RCTs reported required Result retrospective searched secondary secondary outcome Secondary outcomes severity statistically significant Support Symptom Symptoms systematic review tested Treatment variable was performed
[DOI] 10.1111/jep.13614 PMC 바로가기 [Article Type] Review

Add-On Effect of Honeysuckle in the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-Analysis

Pharmacology

Published on 2021-09-152022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

[키워드] 95% confidence interval 95%CI applied Bia Biology C-reactive protein (CRP) China Chinese Clinical efficacy Clinical symptoms Cochrane Library combination therapy Computed tomography coronavirus disease Coronavirus disease 2019 cough COVID-19 curative Data analysis database Effect effective Efficacy and safety enrolled evaluate events Fever honeysuckle identify IMPROVE Inflammatory biomarker Infrastructure journal Laboratory lung Lung CT Medicine Meta-analysis Methodological quality nine outbreak Patient Randomized controlled trial Randomized controlled trials RCT RCTs reducing reduction reported review risk Science searched Severe case severe cases spread to Symptom systematic review technology therapy Treatment Trial trials was used WBC White blood cell with COVID-19
[DOI] 10.3389/fphar.2021.708636 PMC 바로가기 [Article Type] Pharmacology

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews

Review

Published on 2021-09-112022-10-31
Journal: Diagnostics [Category] COVID-19,

[키워드] absence addition Administered administration Adverse reactions analyses Analysis Anti-viral therapy Clinical improvement conducted convalescent plasma COVID-19 database disease severity Efficacy and safety estimate evaluated Evidence for inclusion funding source highlight Hospital stay identify inclusion criteria Infection limitation measurement Methodological quality moderate Mortality Neutralizing antibody titer nine outcome overview Patient performed plasma protocol RCT reduction in review risk of bia Safety Standard therapy Study design systematic literature search systematic review therapy unique Variability viral clearance Web of Science
[DOI] 10.3390/diagnostics11091663 PMC 바로가기 [Article Type] Review

Widespread closure of HIV prevention and care services places youth at higher risk during the COVID-19 pandemic

HIV 예방 및 의료 서비스의 광범위한 폐쇄

Research Article

Published on 2021-09-102022-09-10
Journal: PLoS ONE [Category] 임상,

Ivermectin for Prophylaxis and Treatment of COVID-19: A Systematic Review and Meta-Analysis

Systematic Review

Published on 2021-09-082022-10-31
Journal: Diagnostics [Category] COVID-19,

[키워드] 95% CIs 95% confidence interval Admission adverse event Analysis baseline benefit CIs Clinical efficacy clinical trial registry Control control group COVID-19 decreased mortality Disease progression Evidence fine-tune Guidance include indicated indication intensive care Ivermectin likelihood mechanical ventilation Meta-analysis methodology Mild moderate disease Mortality negative RT-PCR no difference outcome Participants Patient patients Potential treatment Prophylaxis RCT recipient reported Repository review risk Risk of bias SARS-CoV-2 searched severe disease severe pneumonia significantly subjects Support systematic review Treatment treatment for COVID-19 Treatment protocol was used
[DOI] 10.3390/diagnostics11091645 PMC 바로가기 [Article Type] Systematic Review

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

COVID-19 치료를 위한 SARS-CoV-2-중화 단일클론항체

Review

Published on 2021-09-022022-09-11
Journal: The Cochrane database of systematic reviews [Category] SARS, 변종, 임상,

[키워드] 95 % CI 95% CI 95% confidence interval Admission adverse event adverse events AEs all-cause mortality antibody approach average age B cell B cells bamlanivimab Blinding Casirivimab certainty certainty of evidence checked clinical Cochrane COVID-19 Study Register Combination combination therapy conducted coronavirus disease Coronavirus disease 2019 COVID-19 Data collection database death decrease dose Effectiveness etesevimab evaluated event Evidence excluded first test GRADE hospital Hospital admission Hospital admissions hospital discharge hospitalised Host Human identify Imdevimab IMV individual individuals with COVID-19 initial Intervention Invasive mechanical ventilation investigated lack life limitation mAb mAbs maintain moderate monoclonal antibodies monoclonal antibody Mortality NCT04427501 neutralising mAbs nine no effect non-hospitalised occurred outcome oxygen Oxygen requirement participant Participants patients with COVID-19 people with COVID-19 Placebo placebo group placebo treatment potential therapy progression Prophylactic provided Quality of life randomised controlled trial RCT reduce regdanvimab reported risk risk of bia risk ratio RoB2 SAE SAEs Sample size SARS-CoV-2 variant SARS-CoV-2 variants searched Selection Serious Adverse Event Serious Adverse Events severe symptom severe symptoms slight increase Sotrovimab submission Symptom systematic review target the placebo group treat treated Treatment treatment of COVID-19 usual care usual care alone
[DOI] 10.1002/14651858.CD013825.pub2 PMC 바로가기 [Article Type] Review